If a 61-year-old male has a PSA of 5.6 and a biopsy indicates adenocarcinoma with grade group 1, what is the clinical T category assigned?

In the context of prostate cancer staging, the clinical T category is determined based on the findings from the physical examination and imaging studies, as well as the prostate-specific antigen (PSA) levels and biopsy results.

The PSA level of 5.6 is somewhat elevated, which often triggers the need for further evaluation. A biopsy that confirms adenocarcinoma indicates that cancer is present in the prostate. Since the cancer is graded as grade group 1, it suggests that the tumor is well-differentiated with a low likelihood of aggressive behavior.

The classification of cT1c is specifically applied when there is no palpable tumor detected during a digital rectal exam (DRE), but there is evidence of prostate cancer through a biopsy, supported by an elevated PSA level. In this case, since the patient is 61 years old, with a PSA of 5.6 and a biopsy showing adenocarcinoma grade group 1, this combination aligns with the criteria for being classified as cT1c.

The other categories would not be appropriate since cT2 would imply a palpable tumor confined within the prostate, and cT3 would indicate that the cancer has extended beyond the prostate. cTX, which designates that the primary